Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987274 | 0.89 | NAMPT (0.46) | NAMPTROCK2ROCK1DPP9HSP90B1 | |
| SCHEMBL24814393 | 0.89 | NAMPT (0.46) | NAMPTROCK2ROCK1DPP9HSP90B1 | |
| SCHEMBL29986739 | 0.77 | NAMPT (0.44) | NAMPTROCK1DPP9HSP90B1TRAP1 | |
| SCHEMBL24814397 | 0.77 | NAMPT (0.44) | NAMPTROCK1DPP9HSP90B1TRAP1 | |
| SCHEMBL29987272 | 0.76 | ALDH1A1 (0.50) | NAMPTROCK2ROCK1NPC1RAB9A | |
| SCHEMBL24814438 | 0.76 | ALDH1A1 (0.50) | NAMPTROCK2ROCK1NPC1RAB9A | |
| SCHEMBL29986903 | 0.76 | ESR1 (0.40) | NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL24815700 | 0.76 | ESR1 (0.40) | NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL24815671 | 0.76 | ALDH1A1 (0.44) | NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL29986504 | 0.76 | ALDH1A1 (0.44) | NAMPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-29 | — | — | US | disclosed |
| WO-2022251343-A2 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | CISD2, CISD1, FECH | NAMPT 2850/4885ROCK2 3702/4885ROCK1 4679/4885 |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | CISD2, CISD1, FECH | NAMPT 2850/4885ROCK2 3702/4885ROCK1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.